The Me Decade of Cancer

By Sarah Greene The “Me Decade” of Cancer Drugs that target specific tumors are harbingers of a new era of genetically informed medicine. The old rules involving randomized populations may not provide the best answers. Thirty-five years ago journalist Tom Wolfe anointed the ‘70s in America the Me Decade—critiquing the quest for self-actualization via primal-scream therapy, high colonics, and mysticism. The age of social conscious

Written bySarah Greene
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Thirty-five years ago journalist Tom Wolfe anointed the ‘70s in America the Me Decade—critiquing the quest for self-actualization via primal-scream therapy, high colonics, and mysticism. The age of social consciousness and hippie communalism had given way, he suggested, to a reawakening of that quintessentially American quality described by Tocqueville in the 1830s: individualism.

Four decades later, genomics has ushered in its own era of Me, revealing that heterogeneity is the rule, not the exception, when it comes to cancer. According to George Lundberg, former editor of JAMA and the Medscape Journal of Medicine, writing in this month’s Thought Experiment, our rapidly evolving knowledge about the uniqueness of each person’s genome demands a new model of publishing. Journals must reflect the current findings in cancer research, he says, where “the proper study of me is me.” Lundberg’s latest nonprofit organization, Cancer Commons (disclosure: I sit on the editorial board), applies this ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies